CHAPEL HILL, NC, UNITED STATES - Apr 2, 2014 - The Center for Drug Evaluation and Research (CDER) released a new draft guidance on analgesic indications, specifically focusing on clinical drug development and trial design issues. Rho, a full-service contract research organization (CRO), will provide valuable insight on the FDA's new guidance for analgesic indications and will share strategies for analgesic product development, including important considerations in collecting patient reported outcomes, through a free webinar.

WHO:  Ben Vaughn, senior statistical scientist, Rho & Brett Gordon, project director, Rho

WHEN:  Thursday, April 10, 2014, 1:00 p.m. ET/ 10 a.m. PT

Webinar Registration:Strategies for Analgesic Development and the New FDA Guidance for Analgesic Indications

DETAILS:  For media inquiries, please contact Jessica Highsmith at Largemouth Communications, (919) 459-6456, jessica@largemouthpr.com.

ABOUT:  Rho, a privately-held, contract research organization (CRO) located in Chapel Hill, NC, provides a full range of clinical research services across the entire drug development process. For more than 25 years, Rho has been a trusted partner to some of the industry's leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, our innovative technologies, and our therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience. For more information, please visit www.rhoworld.com and follow us on Twitter.